Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.

Robert E. Martell, MD, PhD, Guillermo Garcia-Manero, MD, Anas Younes, MD, Michael Ewer, MD, Iyad N Daher, MD, Michel Drouin, MD, FRCP(C), Wendy Hunt, Karine Lortie, Jennifer Wilhelm, Jeffrey M. Besterman, PhD

Blood (2009) 114 (22): 4756.

https://doi.org/10.1182/blood.V114.22.4756.4756

Published: 2009

Journal Articles

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Anas Younes, MD, Amanda Wedgwood, LPN, Peter McLaughlin, MD, Charalambos Andreadis, MD, Sarit E. Assouline, MD, Zuomei Li, Ph.D, Robert E. Martell, MD, Marja Dubay, BSc., Tracy-Ann Patterson, BSc.N, Michelle R. Ward, MD, Michael Crump, MD

Blood (2007) 110 (11): 2571.

https://doi.org/10.1182/blood.V110.11.2571.2571

Published: 2007

Journal Articles

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, MD, Barbara Pro, MD, Michelle Fanale, MD, Peter McLaughlin, MD, Sattva Neelapu, MD, Luis Fayad, MD, Amanda Wedgwood, RN, APN, Daniela Buglio, MD, Tracy Patterson, RN, Marja Dubay, BSc., Zuomei Li, Ph.D., Robert E. Martell, MD, Ph.D., M. Renee Ward, MD, Ph.D., R. Gregory Bociek, MD, MSc., FRCPC

Blood (2007) 110 (11): 2566.

https://doi.org/10.1182/blood.V110.11.2566.2566

Published: 2007

Journal Articles

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, Virginia Klimek, MD, Jorge Cortes, MD, Farhad Ravandi, MD, Willie M. Newsome, RN, Julie Dumouchel, Marja Dubay, Zoumei Li, Christiane Maroun, Eric Laille, Hagop Kantarjian, MD, Robert E. Martell, MD, Selina Luger, MD

Blood (2007) 110 (11): 444.

https://doi.org/10.1182/blood.V110.11.444.444

Published: 2007

Journal Articles

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, PhD, Francis Giles, MD, Stefan Faderl, Farhad Ravandi, MD, Jorge Cortes, MD, Willie M. Newsome, RN, Jean-Pierre Issa, MD, Tracy-Ann Patterson, Marja Dubay, Zuomei Li, Hagop Kantarjian, MD, Robert E. Martell, MD

Blood (2006) 108 (11): 1954.

https://doi.org/10.1182/blood.V108.11.1954.1954

Published: 2006

Journal Articles

A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).

Guillermo Garcia-Manero, MD, Mark Minden, MD, Zeev Estrov, MD, Srdan Verstovsek, MD, Jackie Fiorentino, RN, Hagop Kantarjian, MD, Gregory Reid, Robert E. Martell, MD, PhD

Blood (2005) 106 (11): 4639.

https://doi.org/10.1182/blood.V106.11.4639.4639

Published: 2005

NARROW

Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

A Phase I Study of the Histone Deacetylase Inhibitor MGCD0103 (MG-0103) Given as a Three-Times Weekly Oral Dose in Patients with Leukemia or Myelodysplastic Syndromes (MDS).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only